Cost-effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy for the Treatment of Atrial Fibrillation: A Canadian Perspective
**Background:** Atrial fibrillation (AF) affects approximately 350,000 Canadians and has an estimated annual economic burden exceeding $800 million dollars. Anti-arrhythmic drug (AAD) therapy and catheter ablation (CA) are the two common treatments for paroxysmal AF. However, the upfront costs of CA...
Saved in:
Main Authors: | Yaariv Khaykin, Peter J. Mallow, John A. Rizzo, Atul Verma, Lauren Chun, Shelby Olesovsky, Matthew R. Reynolds |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2016-10-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://doi.org/10.36469/9837 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Atrial Tachycardias Arising from Ablation of Atrial Fibrillation: A Proarrhythmic Bump or an Antiarrhythmic Turn?
by: Ashok J. Shah, et al.
Published: (2010-01-01) -
Cryoballoon Catheter Ablation in Atrial Fibrillation
by: Cevher Ozcan, et al.
Published: (2011-01-01) -
Catheter ablation versus antiarrhythmic drugs with risk factor modification for treatment of atrial fibrillation: a protocol of a randomised controlled trial (PRAGUE-25 trial)
by: Stepan Havranek, et al.
Published: (2022-06-01) -
The Effects of Catheter Ablation Therapy on Medication Use and Expenditures in Patients with Atrial Fibrillation
by: Matthew R. Reynolds, et al.
Published: (2014-10-01) -
Influence of catheter ablation for atrial fibrillation on atrial and ventricular functional mitral regurgitation
by: Masaharu Masuda, et al.
Published: (2022-06-01)